1 2 9 8 VOLUME 17 | NUMBER 10 | OCTOBER 2011 nature medicine l e t t e r s DNA mismatch repair enzymes (for example, MSH2) maintain genomic integrity, and their deficiency predisposes to several human cancers and to drug resistance. We found that leukemia cells from a substantial proportion of children (~11%) with newly diagnosed acute lymphoblastic leukemia have low or undetectable MSH2 protein levels, despite abundant wild-type MSH2 mRNA. Leukemia cells with low levels of MSH2 contained partial or complete somatic deletions of one to four genes that regulate MSH2 degradation (FRAP1 (also known as MTOR), HERC1, PRKCZ and PIK3C2B); we also found these deletions in individuals with adult acute lymphoblastic leukemia (16%) and sporadic colorectal cancer (13.5%). Knockdown of these genes in human leukemia cells recapitulated the MSH2 protein deficiency by enhancing MSH2 degradation, leading to substantial reduction in DNA mismatch repair and increased resistance to thiopurines. These findings reveal a previously unrecognized mechanism whereby somatic deletions of genes regulating MSH2 degradation result in undetectable levels of MSH2 protein in leukemia cells, DNA mismatch repair deficiency and drug resistance.
l e t t e r s DNA mismatch repair enzymes (for example, MSH2) maintain genomic integrity, and their deficiency predisposes to several human cancers and to drug resistance. We found that leukemia cells from a substantial proportion of children (~11%) with newly diagnosed acute lymphoblastic leukemia have low or undetectable MSH2 protein levels, despite abundant wild-type MSH2 mRNA. Leukemia cells with low levels of MSH2 contained partial or complete somatic deletions of one to four genes that regulate MSH2 degradation (FRAP1 (also known as MTOR), HERC1, PRKCZ and PIK3C2B); we also found these deletions in individuals with adult acute lymphoblastic leukemia (16%) and sporadic colorectal cancer (13.5%). Knockdown of these genes in human leukemia cells recapitulated the MSH2 protein deficiency by enhancing MSH2 degradation, leading to substantial reduction in DNA mismatch repair and increased resistance to thiopurines. These findings reveal a previously unrecognized mechanism whereby somatic deletions of genes regulating MSH2 degradation result in undetectable levels of MSH2 protein in leukemia cells, DNA mismatch repair deficiency and drug resistance.
In humans, DNA mismatches are recognized by one of two hetero dimers, both of which contain MSH2: MutSα (MSH2MSH6) pref erentially recognizes and repairs basebase mismatches as well as small insertion and deletion loops, whereas MutSβ (MSH2MSH3) recognizes and repairs small insertion and deletion loops. DNA poly morphisms (SNPs) and somatic mutations in MSH2 are associated with DNA repair deficiency, leading to genomic instability and a higher risk of certain cancers (for example, hereditary nonpolyposis colon cancer, brain tumors, leukemia and lymphoma) 1, 2 . DNA mismatch repair (MMR) deficiency can also alter the sensitivity of cancer cells to thiopurine chemotherapy, both in vivo and in vitro [3] [4] [5] .
All previously reported mechanisms of MSH2 deficiency directly involve MSH2 through mutations [6] [7] [8] , loss of heterozygosity 9 or pro moter methylation 10 .
Although acute lymphoblastic leukemia (ALL) is now curable in over 80% of affected children, the cause for treatment failure in the remaining children with ALL remains unclear. We and others have reported that primary leukemia cells from a subset of indi viduals with either ALL or acute myeloid leukemia have low levels of MSH2 protein that are caused by mechanisms that have been hitherto unknown 4, 11, 12 .
We initially measured MSH2 protein and mRNA expression in leukemia cells isolated from diagnostic bone marrow aspirates of 90 children with newly diagnosed ALL. The amount of MSH2 protein in each leukemia sample was quantified on the basis of the ratio of MSH2 protein signal to GAPDH signal from the same sample, expressed as relative units (RUs). MSH2 protein levels varied more than tenfold (with a range of <6-102.9 relative units (RU)% and a mean ± s.d. of 36.0 ± 19.8 RU%); notably ALL cells from ten of these children (11.1%) had very low MSH2 levels (<2 ng per 10 6 cells or <8 RU%) ( Fig. 1a and Supplementary Fig. 1a ). Cases with low MSH2 levels also had low levels of MSH6 protein, as would be expected in the absence of MSH2 (ref.13) ( Supplementary Fig. 1b ). We also confirmed the low abundance of MSH2 protein by immunohistochemistry (data not shown).
MSH2 mRNA was expressed similarly in ALL cells with low and high MSH2 protein levels (n = 90, P = 0.63; Fig. 1b ). This was con firmed by quantitative realtime PCR analysis of cells from indivi duals with ALL and low levels of MSH2 (MSH2L ALL) (n = 7) and those with high levels of MSH2 (MSH2H ALL) (n = 10) (data not shown) Moreover, we found no correlation between MSH2 mRNA expression and MSH2 protein expression among ALL cells with high MSH2 protein levels (correlation coefficient r = 0 .1, P = 0.4).
There were no SNPs in MSH2 that differed in frequency between the two MSH2 phenotypes, nor did we find somatic mutations in the MSH2 mRNA of individuals with MSH2L ALL (data not shown). Taken together, this pointed to a posttranscriptional mechanism for the observed MSH2 protein deficiency, consistent with previous studies showing a lack of correlation between MSH2 protein levels and MSH2 mRNA expression in acute myelogenous leukemia cells from affected adults or in drugselected cancer cell lines 12, [14] [15] [16] . The mecha nisms responsible for this discordance in MSH2 mRNA and protein levels in cancer cells are unknown, although the 3′ untranslated region of MSH2 can be targeted by miRNA, thereby causing translational inhibition 17 . Indeed, we found one individual with MSH2deficient leukemia cells who was heterozygous for an MSH2 3′ untranslated region SNP (2846T>G; rs17225053) that creates a miRNA target site, consistent with the reported 2% allele frequency of this SNP. However, given the low frequency of this SNP and its absence in other indivi duals with MSH2L ALL, it did not explain the MSH2L ALL pheno type we found in 11% of these individuals.
Because our previous studies revealed short chromosomal dele tions (<1 Mb) as the predominant copy number alteration in ALL 18 , we examined DNA from leukemia cells in all subjects with sufficient DNA for analysis (7 with MSH2L ALL and 62 with MSH2H ALL) using Affymetrix 6.0 SNP arrays to identify copy number changes in our candidate genes of interest, with an average resolution of approximately 5 kb (ref. 18) . We found no copy number changes in or around the MSH2coding region in any of these individuals. Because absence of PKCζ leads to enhanced degradation of MSH2 (ref. 19) , we initially looked for deletions in PRKCZ in subjects with MSH2 protein defi ciency, revealing deletions in 3 of 7 subjects with MSH2L ALL com pared to only 1 of 62 subjects with MSH2H ALL (adjusted P = 0.0066). We then expanded this analysis to interrogate seven additional genes in the pathway upstream of PRKCZ ( Fig. 1c ; AKT, PIK3C2B, PP2A, FRAP1, HERC1, TSC1 and TSC2). On the basis of chromosomal losses covering at least two consecutive SNPs, we found FRAP1 deletions in 5 of 7 subjects with MSH2L ALL compared to 2 of 62 subjects with MSH2H ALL (adjusted P = 0.00062), HERC1 deletions in 4 of 7 with MSH2L ALL compared to 2 of 62 with MSH2H ALL (adjusted P = 0.020) and PIK3C2B deletions in 2 of 7 with MSH2L ALL compared to 0 of 62 with MSH2H ALL (adjusted P = 0.091). Collectively, all sub jects with MSH2L ALL had deletions of at least one of these four genes, with four individuals having deletions in two or more genes ( Fig. 1d and Supplementary Fig. 2 ). Five of sixtytwo subjects with MSH2H ALL had deletions in one of these genes, but none of the subjects with MSH2H ALL had deletions in more than one of these genes ( Fig. 1d) . Thus, penetrance of the MSH2L phenotype was ~100% (95% confi dence interval (CI) 40-100%) when two or more of these genes had deletions compared to ~58% (95% CI 30-86%) when one or more of these genes had deletions. The frequency of deletions in the other genes in this pathway (TSC1, TSC2, AKT1 and PP2A) was not signifi cantly different in subjects with MSH2L ALL and those with MSH2H ALL (P > 0.4).
In an independent cohort of 170 individuals with ALL, 21 had evidence of deletions of one or more of these four genes (12.3%), a frequency comparable to that seen in the discovery cohort (data not shown). Western blot analysis of leukemia cells from the vali dation cohort (comprising individuals with sufficient cells for ana lysis) revealed that six of seven individuals with deletions of one or more of these four genes had low MSH2 protein levels, whereas none of 14 controls (matched for ALL lineage and molecular subtype) without these deletions had low MSH2 protein levels ( Fig. 1e and Supplementary Fig. 1c ). The one discordant individual with a high abundance of MSH2 protein had a deletion of only one gene (HERC1), whereas all individuals with deletions of two or more genes had low MSH2 protein levels. These data thus fully validated the findings in the discovery cohort.
We confirmed the deletions found in the subjects with MSH2L ALL in the discovery cohort by quantitative PCR in all six individu als with additional DNA for analysis ( Supplementary Table 1 ). Sufficient leukemia cells to perform western blot analysis of the deleted genes were available for two individuals with hemizygous deletions of FRAP1 and two individuals with hemizygous deletions of PRKCZ, documenting ~30-60% lower amounts of the corresponding proteins in individuals with deletions compared to those without these deletions (matched for ALL lineage) ( Fig. 2a) . protein levels in leukemia cells from the validation cohort (all individuals with deletions of one or more of these genes with sufficient cells for western analysis and a 2:1 matched cohort of individuals with ALL but without these deletions). The horizontal lines in a,b and e depict the median values for each cohort.
l e t t e r s
We assessed the microsatellite instability status of DNA in primary ALL cells from individuals with the MSH2L ALL (n = 6) and MSH2H ALL phenotypes (n = 5, matched for ALL subtype) ( Supplementary  Table 2 ), revealing a higher number of markers showing instability in those individuals with MSH2L ALL (Supplementary Fig. 3 and Supplementary Table 3 ).
Among the 252 patients with ALL treated according to the St. Jude Children's Research Hospital Total Therapy XV protocol 20 , we com pared overall survival in the 97 patients for whom we measured MSH2 protein levels in their ALL cells (the overall treatment outcome of the 97 patients was comparable to the entire population of 252 patients; data not shown). There was no difference between the MSH2L and MSH2H cohorts when compared for age, race, ALL genetic subtype, ALL lineage, sex ( Supplementary Table 4 ) or the percentage of cells in S phase (Supplementary Fig. 4 ). Individuals whose ALL cells had low MSH2 levels (n = 16) had a worse overall 10year survival (popu lation estimate ± s.e.m. 78.7% ± 25.7% compared to 97.5% ± 10.8%, respectively, P = 0.009, logrank test) ( Fig. 2b,c) . Moreover, the 10year cumulative incidence of hematological relapse was 20.6% ± 11.2% in the individuals with MSH2L ALL compared to 5.1% ± 2.5% in those with MSH2H ALL (P = 0.06, Gray's test). In a multivariate analysis that included age, race, white blood cell count at diagnosis, ALL lineage (T or B) and the level of minimal residual disease on day 19 of treat ment (n = 92 individuals with all data), MSH2 phenotype remained significantly related to overall survival (P = 0.032, hazard ratio = 17, 95% CI 1.3-231).
The MMR system mediates the cytotoxicity of some DNAdamaging anticancer agents, and the absence of MSH2 has been shown to increase resistance to thiopurines 4, 5, 21 . We determined the sensitivity of human leukemia cells CEM (also known as CCRFCEM) to thiopurines (thioguanine or mercaptopurine) and other antileukemic agents after individual knockdown of each of these genes. The concentrations that killed 50% of cells of thioguanine and mercaptopurine ( Fig. 2d,  Supplementary Fig. 5 and Supplementary Table 5 ) were significantly higher in leukemia cells in which PIK3C2B, HERC1, FRAP1 or PRKCZ had been knocked down (P < 0.02), as previously shown for MSH2 deficiency, whereas these cells were not more resistant to melphalan, daunorubicin, asparaginase, vincristine or glucocorticoids ( Fig. 2d and Supplementary Fig. 5 ). Primary ALL cells from individuals with somatic deletion of one or more of these four genes also showed greater resistance to mercaptopurine (Supplementary Fig. 6 ).
The individual knockdown of each of these genes resulted in a significant reduction in the level of MSH2 protein (in other words, MSH2 protein decreased by 67% to 49% when compared to controls, P < 0.007) ( Fig. 3a-d) . We confirmed this effect by using a second independent short hairpin RNA (shRNA) against each of these genes (Supplementary Fig. 7) . Each of these knockdowns also leads to low MSH6 protein levels ( Fig. 3a-d) , as would be anticipated in the absence of MSH2 (ref. 13) . We further confirmed the effect of FRAP1 inhibition on MSH2 protein levels by the dosedependent effects of rapamycin on MSH2 protein levels (Fig. 3e,f) . We also observed a comparable effect of rapamycin on MSH2 in the human 697 Blineage ALL cell line (Supplementary Fig. 8 ). When we simultaneously knocked down PRKCZ and inhibited FRAP1 with rapamycin, there was an even greater reduction in MSH2 protein (Supplementary Fig. 9 ).
In the control cells after cycloheximide treatment, we found endog enous MSH2 protein to be quite stable, with very little degradation over 48 h (Fig. 3g-h) . After knockdown of PIK3C2B, HERC1, FRAP1 or PRKCZ, there was more rapid loss of MSH2 protein (Fig. 3g-h) . There was increased ubiquitination of MSH2 after inhibition of FRAP1, and the more rapid degradation of MSH2 was blocked by the proteasome inhibitor MG132 (Fig. 3i-j and Supplementary Fig. 10) .
To further elucidate the mechanisms by which these genes influence MSH2 protein levels, we assessed the effects of PIK3C2B, HERC1 and FRAP1 knockdown on PP2A phosphatase activity. FRAP1 is known to inhibit the activation of PP2A, a crucial regulator of PKCζ (encoded by PRKCZ) 22, 23 . HERC1 is a ubiquitin ligase that destabilizes TSC2 (ref. 24) , and TSC2 in complex with TSC1 inhibits FRAP1 function 25, 26 . PI3KC2β (encoded by PIK3C2B) belongs to the class II PI3Ks, but little is known about the physiological function of this class 27 . After knockdown of PIK3C2B, HERC1 or FRAP1, we observed a two fold to threefold increase in PP2A phosphatase activity compared to control (P < 0.01) ( Fig. 4a) . We further showed that knockdown of PIK3C2B decreased the phosphorylation of AKT and P70S6K1 (also known as S6K1) at Ser473 and Thr389, respectively (Fig. 3c) . Likewise, knockdown of HERC1 or FRAP1 decreased P70S6K1 phosphorylation, consistent with mediation of their effects through FRAP1. There was also a dosedependent effect of rapamycin, result ing in a threefold increase of PP2A activity at the highest concen tration (Fig. 4a) . Knockdown of FRAP1, HERC1 or PIK3C2B led to a reduction in PKCζ phosphorylation (activation), an anticipated consequence of increased PP2A activity (Fig. 4b,c) . To determine whether the decrease in MSH2 protein levels is through modulation of PP2A activity, we assessed the effects of the phosphatase inhibitor okadaic acid (at 10 nM). Okadaic acid treatment increased PKCζ phosphorylation (meaning PKCζ activation) and restored MSH2 protein levels in cells in which either HERC1, FRAP1 or PIK3C2B had been knocked down (Fig. 4b,c) .
To assess the functional consequences of HERC1, FRAP1, PIK3C2B or PRKCZ knockdowns, we measured DNA mismatch repair activity using nuclear extracts from CEM cells after knockdown of HERC1, FRAP1, PIK3C2B or PRKCZ and from NALM6 cells as an MSH2 deficient control. We observed that knockdown of FRAP1, HERC1, PIK3C2B or PRKCZ produced an approximately 50% reduction in MSH2 protein, leading to a significant reduction in DNA mismatch repair capacity in human leukemia cells (Fig. 4d) . These results are consistent with a haploinsufficiency model for MSH2's effects on DNA mismatch repair, as previously reported [28] [29] [30] . This reduction in MMR capacity was rescued by adding 0.2 µg of purified MutSα to the repair reactions (Fig. 4d) . The decrease in MMR function was comparable to the reduction in MMR observed following partial immune depletion of MSH2 (Fig. 4e,f) .
To determine whether deletion of these four genes occurs in other human cancers, we analyzed publicly available datasets for sporadic colorectal cancer and adult ALL. In the colorectal dataset 31 , 14 of 104 individuals (13.5%) had deletions of one or more of these four genes ( Supplementary Table 6 ). In the adult ALL cohort 32 , deletions of one or more of these four genes were detected in 7 of 45 individuals (16%) (Supplementary Table 7) . About 15% of sporadic colorectal cancers have been reported to have a high level of microsatellite instability. Hypermethylation of the MLH1 promoter region frequently causes inactivation of this gene, but this does not explain all instances of spo radic colon cancer with the MSIH phenotype. Prior work has shown that MSH2 protein expression was absent in ~15% of instances of spo radic colon cancer (7 of 46 individuals), and of these 7 individuals, only 2 had loss of heterozygosity or somatic mutation of MSH2 (ref. 33 ). 
For the majority of these individuals with colon cancer (five of seven) with low MSH2 protein (~11% of the total), the mechanism leading to low MSH2 protein was not identified. It is plausible that these instances of disease may be caused by deletions of genes regulating MSH2 protein stability.
In conclusion, inactivation of DNA mismatch repair genes is known to be involved in the pathobiology of certain hereditary and sporadic cancers and has been associated with mutator phenotypes, inhibition of apoptosis, defective cell cycle arrest and chemotherapy resistance [34] [35] [36] . However, neither the genomic cause nor the func tional consequences of MSH2 deficiency in primary leukemia cells has been previously established. The current work has identified a new genomic mechanism by which the leukemia cells of approxi mately 11% of individuals with newly diagnosed ALL acquire MSH2 deficiency with multiple downstream consequences, and we found evidence that these same somatic deletions occur in sporadic colon cancer and other human malignancies.
MeTHoDS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. oNLINe MeTHoDS Subjects with ALL (initial discovery and validation cohorts). We initially studied 90 patients (age ≤21 years) who had newly diagnosed ALL and were enrolled in the St. Jude Total Therapy XV protocol. To validate our findings, we subsequently studied an additional 170 patients with ALL enrolled on the same treatment protocol using publicly available SNP data we had previously reported 17 . The treatment and research protocol was approved by the institutional review board of St. Jude Children's Research Hospital, and informed consent was obtained from subjects, their guardians or both before enrollment. Assent was also obtained from patients who were 14 years old or older. The diagnosis of ALL was based on previously described morphological and molecular criteria. Leukemia cells were isolated by applying a FicollHypaque gradient to bone marrow aspirates obtained at diagnosis (with a median of 97% blast cells). Normal leukocytes were isolated from peripheral blood samples obtained after the successful completion of remission induction therapy (on days 45-48 after the start of treatment).
Affymetrix 600K SNP array analyses.
To assess gene copy number loss in MSH2L leukemia cells, DNA was extracted from leukemia cells and normal peripheral blood leukocytes (obtained when patients were in complete remis sion) and genotyped for 600K SNPs using the Affymetrix GeneChip Human Mapping 50K Hind 240, 50K Xba 240, 250K Sty and 250K Nsp SNP arrays. DNA was restriction enzyme digested, PCR amplified, purified, labeled, fragmented and hybridized to the arrays according to the manufacturer's instructions. SNP array data were analyzed using dChip (http://biosun1.harvard.edu/complab/ dchip/) for chromosomal abnormalities. To improve the accuracy of copy number inference using dChip, we applied a normalization procedure that uses SNPs exclusively from regions shown to be diploid in the normal leukocytes and maps signals from those SNPs to a common target probability distribution. The SNPs with an estimated copy number lower than 1.40 were considered as evidence of deletions 17 .
We initially performed SNP analysis on PRKCZ because it is known to regu late MSH2 stability. This led us to subsequently perform a broader pathway analysis to interrogate additional genes upstream of PRKCZ (Fig. 1c) . This analy sis included eight genes and a total of 122 SNPs. For each SNP, we evaluated the overrepresentation of deletions in MSH2L leukemia cells compared to MSHH leukemias using a Fisher's Exact test. The significance of each SNP was then adjusted for multiple testing using 100,000 permutations. At each per mutation, we recorded the smallest P value among all the 122 SNPs based on randomly assigned MSH2 status. The adjusted P values were computed as the proportion of permutations whose smallest P values were lower than or equal to the observed value.
Cell culture. The human T lineage leukemia cell line CCRFCEM was obtained from the American Type Culture Collection. The human preB leukemia cell lines 697 and NALM6 were obtained from the German Collection of Microorganisms and Cell Cultures. Cells were cultured in RPMI1640 medium containing 2 mM glutamine and 10% (vol/vol) FBS at 37 °C with 5% CO 2 .
Stable short hairpin RNA (shRNA) knockdowns. CCRFCEM cells were infected with MISSION lentiviral transduction particles (SigmaAldrich) pro duced from a library of sequenceverified shRNAs targeting human PIK3C2B, FRAP1 (MTOR), HERC1 or PRKCZ transcripts. Nontarget shRNA control particles (SHC002V) were also purchased from SigmaAldrich. Individual cell clones were isolated in medium containing puromycin.
Statistical analyses.
A Fisher's exact test was used to test the overrepresentation of losses among subjects with low MSH2 compared to those with high MSH2 levels. A Fisher's exact test was performed at the singleSNP level. A linear regression model was used to test the correlation between the levels of MSH2 mRNA and protein. The expression levels of the probe sets were analyzed by applying a general linear model in which the effect of MSH2 status (low or high) was adjusted for the ALL genetic subtypes. Overall survival rates were compared using a stratified MantelHaenszel test. A Cox proportional hazards model was used to identify the independent prognostic effect of MSH2 sta tus. For patients who achieved complete remission, the cumulative incidence of hematological relapse were constructed by the method of Kalbfleisch and Prentice and compared with the results from Gray's test. All other failures were considered competing events. A FineGray model was used to identify inde pendent prognostic factors.
Additional methods. Detailed methodology is described in the Supplementary Methods and Supplementary Table 8 .
